Abstracts tagged "methotrexate (MTX) and rheumatoid arthritis (RA)"

Abstract Number: 1043 • 2015 ACR/ARHP Annual Meeting
Enhancing Comparative Effectiveness Research By Combining Observational and Randomized Trial Data to Personalize the Choice Between Methotrexate and Triple Therapy for Methotrexate-Naïve Patients with Early Rheumatoid Arthritis
Glen S. Hazlewood^1,2, Cheryl Barnabe³, Gilles Boire⁴, Carol Hitchon⁵, Edward C. Keystone⁶, Boulos Haraoui⁷, J Carter Thorne⁸, Diane Tin⁹, Janet E. Pope¹⁰, Daming Lin¹¹, VP Bykerk¹² and CATCH investigators, ¹Institute of Health, Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ²Medicine, University of Calgary, Calgary, AB, Canada, ³Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁴Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁵University of Manitoba, Winnipeg, MB, Canada, ⁶Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁷Institut de Rhumatologie, Montreal, QC, Canada, ⁸Southlake Regional Health Centre, Newmarket, ON, Canada, ⁹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁰University of Western Ontario, London, ON, Canada, ¹¹Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹²Hospital for Special Surgery, Weill Cornell Medical College, New York, NY
Background/Purpose: Randomized controlled trials (RCTs) are considered the gold standard for comparing efficacy of treatments, but the results may be less generalizable to clinical practice…
Abstract Number: 1045 • 2015 ACR/ARHP Annual Meeting
Baricitinib, Methotrexate, or Baricitinib Plus Methotrexate in Patients with Early Rheumatoid Arthritis Who Had Received Limited or No Treatment with Disease-Modifying Anti-Rheumatic Drugs (DMARDs): Phase 3 Trial Results
Roy Fleischmann¹, Tsutomu Takeuchi², Douglas E. Schlichting³, William L. Macias³, Terence Rooney³, Sirel Gurbuz³, Ivaylo Stoykov³, Scott D. Beattie³, Wen-Ling Kuo³ and M Schiff⁴, ¹Rheumatology, Metroplex Clinical Research Center, Dallas, TX, ²Keio University School of Medicine, Tokyo, Japan, ³Eli Lilly and Company, Indianapolis, IN, ⁴School of Medicine, University of Colorado, Denver, CO
Background/Purpose: In 2 completed phase 3 studies, baricitinib (bari) improved disease activity with a satisfactory safety profile in patients (pts) with moderately-to-severely active RA who…
Abstract Number: 1538 • 2015 ACR/ARHP Annual Meeting
Clinical Analysis of 30 Rheumatoid Arthritis Patients Complicated with Malignant Lymphoma, Especially Methotrexate-Related Lymphoproliferative Disorder
Takuma Tsuzuki Wada¹, Yuji Akiyama¹ and Toshihide Mimura², ¹Department of Rheumatology & Applied Immunology, Faculty of Medicine, Saitama Medical University, Iruma, Japan, ²Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan
Background/Purpose: Recently, methotrexate (MTX) has been considered as the anchor drug in the treatment of rheumatoid arthritis (RA). However, it has been reported that MTX…
Abstract Number: 1613 • 2015 ACR/ARHP Annual Meeting
Expression of the Genes Facilitating Methotrexate Action within Rheumatoid Subcutaneous Nodules
Emma Houlder¹, Melanie Millier², John Highton³, Lisa K. Stamp⁴ and Paul Hessian², ¹Medicine, University of Otago, Dunedin, New Zealand, ²Department of Medicine, University of Otago, Dunedin, New Zealand, ³Dept of Medicine, University of Otago, Dunedin, New Zealand, ⁴Medicine, University of Otago, Christchurch, Christchurch, New Zealand
Background/Purpose: Methotrexate (MTX) is the most frequently used DMARD in the treatment of rheumatoid arthritis (RA). There are known links between the use of MTX…
Abstract Number: 2107 • 2015 ACR/ARHP Annual Meeting
Initiation of Combination Triple Therapy in Real World Clinical Practice Rarely Replicates the Protocols Used in Randomized Controlled Trials.
Grant W. Cannon¹, Chia-Chen Teng², Ted R. Mikuls³, Jeffrey R. Curtis⁴, Derek Tang⁵, Bradley S. Stolshek⁵ and Brian Sauer⁶, ¹Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ³Veteran Affairs Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Amgen, Inc., Thousand Oaks, CA, ⁶Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT
Background/Purpose: Combination therapy with methotrexate (MTX), sulfasalazine (SUL), and hydroxychloroquine (HCQ) [triple therapy] is an effective treatment for rheumatoid arthritis (RA). Randomized controlled trials…
Abstract Number: 2606 • 2015 ACR/ARHP Annual Meeting
Serum Myeloid Related Protein 8/14 Levels in Rheumatoid Arthritis: Marker of Disease Activity and Response to Methotrexate in DMARD Naïve Patients
Pradeepta Sekhar Patro, Ankita Singh, Ramnath Misra and Amita Aggarwal, Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: MRP8/14 are calcium binding proteins produced by myeloid cells. Recently baseline serum levels of MRP8/14 have been shown to predict response to biologicals in…
Abstract Number: 2618 • 2015 ACR/ARHP Annual Meeting
Methotrexate Dose May Associated with the Frequency of Lymphoproliferative Disorders in Rheumatoid Arthritis
Hiroaki Dobashi¹, Tomohiro Kameda¹, Masayuki Inoo², Ikuko Onishi², Noriyuki Kurata², Miharu Izumikawa¹, Yohei Takeuchi³, Shusaku Nakashima¹, Hiromi Shimada¹, Hiroki Ozaki¹, Risa Wakiya¹ and Norimitsu Kadowaki⁴, ¹Internal Medicine Division of Hematology, Rheumatology, and Respiratory Medicine, Kagawa University, Kagawa, Japan, ²Utazu hospital, Kagawa, Japan, ³Internal Medicine Division of Endocrinology and Metabolism, Hematology, Rheumatology and Respiratory Medicine, Kagawa University, Kagawa, Japan, ⁴Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University,, Kagawa, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a systemic inflammatory disease that is characterized by synovitis and the destruction of articular structures of multiple joints. The goal…
Abstract Number: 1040 • 2014 ACR/ARHP Annual Meeting
Dysregulated Serum Interleukin 16 Concentration Associated with Clinical Disease Activity in Patients with Rheumatoid Arthritis Is Efficiently Corrected By Immunological Intervention
Atsuko Murota¹, Katsuya Suzuki¹, Yoshiaki Kassai², Takahiro Miyazaki³, Rimpei Morita⁴, Akihiko Yoshimura⁴ and Tsutomu Takeuchi¹, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Takeda Pharmaceutical Company, Fujisawa, Japan, ³Inflammation Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan, ⁴Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: IL-16 is a chemoattractant factor that evokes massive infiltration of mononuclear cells in the synovial tissue in patients rheumatoid arthritis (RA). IL-16 concentrations are…
Abstract Number: 503 • 2014 ACR/ARHP Annual Meeting
Does a Higher Dose of Folic Acid Reduce Adverse Effects of Methotrexate in Rheumatoid Arthritis? a Randomized Controlled Trial
Varun Dhir¹, Amit Sandhu¹, Jasbinder Kaur², Nidhi Gupta¹, Prabhdeep Kaur¹, Ankita Sood¹, Aman Sharma³ and Shefali Sharma¹, ¹Postgraduate Institute of Medical Education and Research, Chandigarh, India, ²Government Medical College and hospital Sector 32, Chandigarh, India, ³Internal Medicine (Rheumatology Unit), Postgraduate Institute of Medical Education and Research, Chandigarh, India
Background/Purpose There is good evidence that folic acid 5-10mg per week leads to reduction in methotrexate (MTX) toxicity in rheumatoid arthritis (RA). However, this data…
Abstract Number: 2915 • 2014 ACR/ARHP Annual Meeting
Effects of Methotrexate on Anti-TNF Treatment in Rheumatoid Arthritis: An in-Depth Analysis of a Prospective Observational Study with Adalimumab
Marc Schmalzing¹, Frank Behrens^2,3, Eva C. Scharbatke¹, Michaela Koehm^3,4, Bianca Wittig⁵, Gerd Greger⁶, Harald Burkhardt^2,7 and Hans-Peter Tony⁸, ¹Rheumatology/Immunology, University of Würzburg, Würzburg, Germany, ²Rheumatology, Goethe-University Frankfurt, Frankfurt, Germany, ³Clinical Research, Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine & Pharmacology TMP, Frankfurt/Main, Germany, ⁴Rheumatology, Goethe-University Frankfurt, Frankfurt/Main, Germany, ⁵Abbvie Deutschland GmbH & Co. KG, Wiesbaden, Germany, ⁶AbbVie GmbH & Co KG, Wiesbaden, Germany, ⁷Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine & Pharmacology TMP, Frankfurt/Main, Germany, ⁸Rheumatology/Clinical Immunology, University of Würzburg, Würzburg, Germany
Background/Purpose Methotrexate (MTX) is currently the most frequently used drug in the treatment of rheumatoid arthritis (RA). MTX co-medication can improve the therapeutic benefit of…
Abstract Number: 498 • 2014 ACR/ARHP Annual Meeting
Patient Experience with Initiation of SQ and Oral MTX
Jeffrey R. Curtis¹, David Mackey², Noam Gerber³, Aseem Bharat¹, Lang Chen⁴, Fenglong Xie⁵, Ben Nowell³, Kenneth G. Saag⁶ and Seth Ginsberg⁷, ¹University of Alabama at Birmingham, Birmingham, AL, ²Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Creaky Joints/Global Healthy Living Foundation, Upper Nyack, NY, ⁴Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁵Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ⁶Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ⁷CreakyJoints/Global Healthy Living Foundation, Upper Nyack, NY
Background/Purpose Methotrexate is the anchor drug used for the treatment of rheumatoid arthritis (RA). Despite its prominent position in RA therapeutics, its real-world effectiveness may…
Abstract Number: 2890 • 2014 ACR/ARHP Annual Meeting
Does a Family History of RA Influence the Clinical Presentation and Treatment Response in RA?
Thomas Frisell¹, Saedis Saevarsdottir^2,3 and Johan Askling^1,4, ¹Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, ²Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ³Rheumatology Unit, Dept. of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, ⁴Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Since family history of RA is among the strongest risk factors for developing the disease, individuals suspected to have RA are routinely asked about…
Abstract Number: 470 • 2014 ACR/ARHP Annual Meeting
Safety Profile of Biologic Agents for Rheumatoid Arhtisitis Treatment after the Complication with Methotrexate-Related Lymphoproliferative Disorder
Shuntaro Saito¹, Yuko Kaneko¹, Katsuya Suzuki¹, Michihide Tokuhira² and Tsutomu Takeuchi¹, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Department of Hematology., Saitama Medical Center, Saitama Medical University., Saitama, Japan
Background/Purpose Lymphoproliferative disorder (LPD) is a rare complication in patients with rheumatoid arthritis(RA) treated with methotrexate(MTX). Although not a few patients experience exacerbation of RA…
Abstract Number: 2494 • 2014 ACR/ARHP Annual Meeting
Persistence on Single Disease Modifying Anti-Rheumatic Drug Therapy in US Veterans with Rheumatoid Arthritis Is Extremely Rare
Jonathan Kruger¹, Michael Morgan¹, Andreas Reimold², Ted R. Mikuls³, Gail Kerr⁴ and Grant W. Cannon⁵, ¹Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT, ²Rheumatology, Dallas VA and Univ of TX Southwestern Med Ct, Dallas, TX, ³Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁴Rheumatology, Washington DC VA and Georgetown and Howard University, Washington, DC, ⁵Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT
Background/Purpose: Few rheumatoid arthritis (RA) patients are managed successfully with a single disease modifying anti-rheumatic drug (DMARD). This investigation determined the prevalence and clinical…
Abstract Number: 2510 • 2014 ACR/ARHP Annual Meeting
Good Response to Methotrexate (MTX) and/or MTX Plus Adallimumab (ADA): 3 Yrs Study Results in Patients with Rheumatoid Arthritis (RA)
Kazuko Shiozawa¹, Takashi Yamane², Miki Murata¹, Chihiro Tanaka¹, Noriaki Yo², Ryosuke Yoshihara¹, Yasushi Tanaka¹, Ken Tsumiyama³ and Shunichi Shiozawa⁴, ¹The Rheumatic Diseases Center, Kohnan Kakogawa Hospital, Kakogawa, Japan, ²Kohnan Kakogawa Hospital, Kakogawa, Japan, ³Department of Rheumatology, Kyushu University Beppu Hospital, Beppu, Japan, ⁴Department of Medicine, Rheumatic Diseases Unit, Kyushu University Beppu Hospital, Beppu, Japan
Background/Purpose: To achieve comprehensive disease control (CDC; defined as simultaneous achievement of DAS28 < 3.2, HAQ-DI < 0.5 and ΔmTSS ≤ 0.5) or comprehensive disease…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].